Trial Profile

A Phase 1b Study of Ensartinib in Combination With Platinum-Based Chemotherapy and Bevacizumab in ALK-Positive Non-Small Cell Lung Cancer (NSCLC)

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 25 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bevacizumab (Primary) ; Carboplatin (Primary) ; Ensartinib (Primary) ; Pemetrexed (Primary)
Indications Brain metastases; Non-small cell lung cancer
Focus Adverse reactions

Most Recent Events

04 Jun 2024 Results (as of 12 Jan 2024) reporting safety and efficacy analysis presented at the 60th Annual Meeting of the American Society of Clinical Oncology
05 Jan 2023 Planned End Date changed from 23 Sep 2022 to 23 Sep 2027.
05 Jan 2023 Planned primary completion date changed from 23 Sep 2022 to 23 Sep 2027.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com